4 results
Approved WMOCompleted
To determine the safety and efficacy of Dimebon in patients with mild-to-moderate Huntington Disease
Approved WMOCompleted
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
Approved WMOCompleted
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
Approved WMOCompleted
Phase 1b:Primary:- To evaluate the safety and tolerability and determine the recommended Phase 2 dose (RP2D) and schedule of ALRN-6924 when administered to patients with TP53-mutated extensive disease (ED) small cell lung cancer (SCLC) receiving…